Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Week in Review: Regor Sells Two CDK Inhibitors to Genentech for $850m
Deals and Financings
Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors (CDKIs) aimed at breast cancer (see story). Regor will receive $850 million upfront, a hefty amount for two Phase I candidates. The company will also be eligible for an undisclosed amount of milestone payments, both developmental and commercial. Roche, Genentech’s parent, said the novel candidates add new targets to its stable of three existing breast cancer drugs (plus a fourth candidate up for FDA approval).
Kailera Therapeutics launched with a four-drug pipeline aimed at the very crowded target of obesity (see story). The company was formed by four US venture capital companies who funded the startup in a $400 million Series A round. In May, Jiangsu Hengrui announced a $6 billion deal, heavily backloaded, with Kailera, then known as Hercules. Hengrui also received a 19.9% share of Kailera as part of the deal. Kailera, with facilities in the Boston area and San Diego, now has an experienced biopharma CEO, a Board of Directors, and a portfolio of Hengrui’s obesity candidates.
Caliway Biopharmaceuticals IPO’d on the Taiwan Exchange (TWSE-6919) to support its portfolio of medical aesthetic and inflammatory disease candidates (see story). The listing, which valued the company at nearly $3 billion, raised $206 million. It is a record for the largest IPO of a biopharma company in Taiwan’s history. Caliway is ready to start Phase III trials of its lead product, CBL-514, an injection that induces adipocyte apoptosis to reduce subcutaneous fat in targeted areas.
Flagship Pioneering, a Cambridge, MA company, and Singapore’s A*STAR formed a collaboration to back new Singapore-based health and sustainability companies (see story). In a MOU, the two companies agreed to contribute a total of US$77 million over five years, with the goal of creating new companies in Singapore. Flagship, a combination of startup and venture capitalist, forms its own companies with its own capital. The process starts with a “farfetched” question that sometimes becomes a company if the concept seems viable. Flagship supports the young company initially but expects other VCs to fund later development.
Hong Kong’s GenEditBio received a “strategic investment” from AEF Greater Bay Area Fund, which is managed by Gobi Partners GBA (see story). Although the size of the venture capital funding was not disclosed, the three-year-old company doesn’t appear to have any trouble raising money. Earlier this year, it closed a $90 million round and didn’t publicize the milestone. GenEditBio plans to offer affordable "precision DNA surgery" for genetic diseases, replacing life-long therapies with a one-and-done gene therapy.
Disclosure: none.
Upcoming Events
BIO-Europe®
Register here
Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Other Relevant Events
Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here